Clinical Trial Detail

NCT ID NCT01820364
Title LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

Therapies

Binimetinib + Encorafenib

Encorafenib + Ribociclib

Buparlisib + Encorafenib

Encorafenib + Infigratinib

Capmatinib + Encorafenib

Age Groups: adult

Additional content available in CKB BOOST